Skip to main content
Circio Holding ASA logo

Circio Holding ASA — Investor Relations & Filings

Ticker · CRNA ISIN · NO0013033795 LEI · 5967007LIEEXZXFYNS31 OL Professional, scientific and technical activities
Open in API
Filings indexed 167 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country NO Norway
Listing OL CRNA

About Circio Holding ASA

https://www.targovax.com/en/

Circio Holding ASA is a clinical-stage company developing novel medicines based on circular RNA (circRNA) and immunotherapy. The company's core focus is its proprietary circVec platform, a circular RNA expression system designed to enhance the efficacy and durability of gene and cell therapies. Circio's development pipeline is directed towards immuno-oncology, targeting difficult-to-treat solid tumors, and the application of its circRNA technology to address genetic diseases.

Recent filings

Filing Released Lang Actions
Circio Holding ASA: Exercise price for Warrants set at NOK 8.2508
Capital/Financing Update Classification · 96% confidence The document is a press release announcing the exercise price for warrants issued in connection with a rights issue and private placement. It details terms, dates, and financing instructions under the warrant program. This is an update on the company’s capital structure and financing activities rather than a full report, regulatory certification, or proxy filing. Therefore, it fits the Capital/Financing Update category.
2026-05-22 English
Circio invites to a live webcast on 28 May 2026 to summarize the presentations at ASGCT 2026 and provide an overview of the warrants program
Capital/Financing Update Classification · 72% confidence The document is a stock exchange announcement inviting investors to a live webcast summarizing presentations at a scientific meeting and providing an overview of the company’s warrant program and planned use of proceeds. It is not a full financial report, regulatory certification, or voting notice, but rather an update on the company’s financing activity (warrant exercise period, subscription terms, use of proceeds). This fits the definition of a Capital/Financing Update (CAP).
2026-05-22 English
Circio files EPO patent application covering critical aspects of its circVec platform for enhanced gene and cell therapy
Regulatory Filings Classification · 72% confidence The document is a press release announcing that Circio has filed an EPO patent application (intellectual property event). It contains no financial statements, earnings, management changes, dividend notices, share transactions, or other specific corporate filings, and is not the publication of a report itself. None of the defined specialized categories match a patent filing announcement. Therefore, it falls into the fallback category Regulatory Filings (RNS).
2026-05-21 English
Circio presents new and extensive circVec data at ASGCT supporting substantial AAV dose reduction - Attachment: 260515 ASGCT Circio.pdf
Investor Presentation Classification · 75% confidence The document is a slide deck presented by the CEO at an external (scientific) annual meeting, containing strategic technology and development pipeline overviews in a presentation format. It does not contain actual financial statements or regulatory disclosures, nor is it a short announcement. It fits the definition of an Investor Presentation (detailed presentation for stakeholders on strategy, technology, and milestones).
2026-05-15 English
Circio presents new and extensive circVec data at ASGCT supporting substantial AAV dose reduction - Attachment: 2026 ASGCT Poster.pdf
Regulatory Filings Classification · 10% confidence The document is a scientific conference poster abstract presented at ASGCT 2026, detailing experimental methods, figures and conclusions on gene therapy. There is no mention of financial results, regulatory filings, corporate governance, dividends, capital transactions, or any other corporate disclosure context. It does not fit any specific financial or corporate filing category. Therefore, by elimination, it is classified under the fallback category Regulatory Filings (RNS).
2026-05-15 English
Circio presents new and extensive circVec data at ASGCT supporting substantial AAV dose reduction
Regulatory Filings Classification · 85% confidence The document is a press release announcing that Circio has published and presented new scientific data (poster and slides) at the ASGCT conference. It is not an Annual or Interim Report, Earnings Release, Financing Update, Management change, or other specific high-level filing. It is a general regulatory announcement of inside information under MAR, disclosing scientific presentation materials. Therefore, the best fit is Regulatory Filings (RNS) as a miscellaneous announcement that does not fit more specific categories.
2026-05-15 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.